SCHEMBL30539895

SCHEMBL30539895

c1ccc2c(c1)ncc1n[nH]cc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR3 P46089 3/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ MAPT P10636 1/20 0.41
▸ TOP2A P11388 2/20 0.41
▸ CYP3A4 P08684 1/20 0.38
▸ PDPK1 O15530 2/20 0.37
▸ CA12 O43570 1/20 0.37
▸ PARP1 P09874 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ TNKS2 Q9H2K2 1/20 0.37
▸ ERN1 O75460 1/20 0.37
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ NCF1 P14598 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ PI4KA P42356 1/20 0.35
▸ PI4K2B Q8TCG2 1/20 0.35
▸ PI4K2A Q9BTU6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL253096 1.00 GPR3 (0.50) GPR3KDM4EMAPTTOP2ACYP3A4
SCHEMBL2048246 0.79 PDPK1 (0.47) GPR3KDM4EMAPTTOP2ACYP3A4
SCHEMBL9837615 0.78 MAPT (0.67) KDM4EMAPTCYP3A4SMN1; SMN2ERN1
SCHEMBL729397 0.76 KDM4E (0.47) KDM4EMAPTCYP3A4ALOX15SMN1; SMN2
SCHEMBL729398 0.76 LMNA (0.45) KDM4EMAPTCYP3A4SMN1; SMN2
SCHEMBL1727666 0.73 KDM4E (0.52) GPR3KDM4ETOP2APDPK1CYP1A2
SCHEMBL30951595 0.73 KDM4E (0.52) GPR3KDM4ETOP2APDPK1CYP1A2
SCHEMBL30665271 0.73 KDM4E (0.47) GPR3KDM4EMAPTTOP2ACYP3A4
SCHEMBL19020845 0.73 GPR3 (0.68) GPR3KDM4EMAPTTOP2ACYP3A4
SCHEMBL8763443 0.71 ALDH1A1 (0.52) GPR3KDM4EMAPTCYP3A4SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112521387-B NLRP3 modulators 先天肿瘤免疫公司 2023-08-22 — — CN disclosed
Send feedback